Posterior reversible encephalopathy syndrome: Difference between revisions
(New Page) |
(Add peer-reviewed references with PMIDs) |
||
| (29 intermediate revisions by 10 users not shown) | |||
| Line 1: | Line 1: | ||
==Background== | ==Background== | ||
* | *Clinical-radiographic syndrome characterized by '''headache, seizures, visual disturbances, and altered mental status''' with '''vasogenic edema''' predominantly in posterior brain regions<ref>Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914-925. PMID 26184985</ref> | ||
* | *Previously known as reversible posterior leukoencephalopathy syndrome (RPLS) | ||
** | *Usually reversible with prompt treatment of underlying cause, but can be irreversible if untreated (cytotoxic edema, hemorrhage) | ||
** | *Pathophysiology (two proposed mechanisms): | ||
**Hypertensive theory: severe hypertension exceeds cerebral autoregulation → hyperperfusion → vasogenic edema (posterior brain more vulnerable due to less sympathetic innervation) | |||
== | **Endothelial dysfunction theory: direct endothelial injury from toxins, medications, or autoimmune activation → blood-brain barrier disruption → vasogenic edema | ||
===Common Causes=== | |||
*'''Hypertensive emergency''' (most common; including [[eclampsia]]/[[preeclampsia]]) | |||
*Immunosuppressive/cytotoxic medications: cyclosporine, tacrolimus, cisplatin, bevacizumab, methotrexate | |||
*Autoimmune conditions: [[SLE]], [[thrombotic thrombocytopenic purpura]], [[hemolytic uremic syndrome]] | |||
*Renal failure (especially with fluid overload) | |||
*[[Eclampsia]]/[[preeclampsia]] (most common cause in young women) | |||
*[[Sepsis]], [[shock]], organ transplantation | |||
==Clinical Features== | |||
*Headache (most common presenting symptom) | |||
*Seizures (60-75% of cases; may be the presenting feature) | |||
*Visual disturbances: blurred vision, cortical blindness, visual neglect, homonymous hemianopia | |||
*'''Altered mental status''': confusion, obtundation, decreased alertness | |||
*Focal neurologic deficits (less common but can occur) | |||
*Hypertension (present in 70-80% but PRES can occur with normal BP in 20-30% of cases) | |||
*Nausea, vomiting | |||
==Differential Diagnosis== | ==Differential Diagnosis== | ||
*[[Ischemic stroke]] (especially posterior circulation) | |||
*[[Cerebral venous sinus thrombosis]] | |||
*[[Encephalitis]] | |||
*CNS vasculitis | |||
*Toxic leukoencephalopathy | |||
*Demyelinating disease (ADEM) | |||
*[[Subarachnoid hemorrhage]] | |||
*[[Status epilepticus]] | |||
*'''CNS metastatic disease''' | |||
==Evaluation== | |||
===MRI (Diagnostic Study of Choice)=== | |||
*MRI with FLAIR and DWI is the gold standard | |||
*Classic pattern: bilateral, symmetric vasogenic edema in parieto-occipital white matter | |||
*FLAIR/T2: hyperintense signal in affected regions | |||
*DWI/ADC: elevated ADC (vasogenic edema) vs restricted diffusion (cytotoxic edema → worse prognosis) | |||
== | *Atypical patterns (30-40%): frontal lobe, temporal lobe, cerebellum, brainstem, unilateral, hemorrhagic | ||
* | *Hemorrhage occurs in 5-15% of cases (petechial or frank hemorrhage) | ||
== | |||
* | ===CT Head=== | ||
*May show hypodensity in posterior regions but sensitivity is low | |||
*Useful to rule out hemorrhage or ischemic stroke initially | |||
*If MRI unavailable, CT findings may be suggestive but are often subtle | |||
===Labs=== | |||
*BMP (renal function, electrolytes) | |||
*CBC with smear (evaluate for TMA — schistocytes if TTP/HUS) | |||
*LFTs, LDH, haptoglobin (hemolysis workup) | |||
*Urinalysis (proteinuria if eclampsia) | |||
*Magnesium level | |||
*Drug levels (cyclosporine, tacrolimus) | |||
*Pregnancy test in reproductive-age women | |||
==Management== | ==Management== | ||
===Blood Pressure Control (If Hypertensive)=== | |||
*Gradual reduction — target 25% reduction in MAP in first few hours | |||
*Avoid precipitous drops (risk of posterior circulation ischemia) | |||
*Preferred agents: | |||
**Nicardipine infusion 5-15 mg/hr (easily titratable) | |||
**Labetalol 10-20 mg IV q10-20min | |||
*If eclampsia: magnesium sulfate is first-line for seizure prevention (see [[eclampsia]]) | |||
===Seizure Management=== | |||
*Benzodiazepines for acute seizures (lorazepam 2-4 mg IV) | |||
*AEDs for ongoing seizure prophylaxis (levetiracetam preferred) | |||
*If eclampsia: magnesium sulfate (primary treatment) | |||
*Most seizures resolve with BP control and treatment of underlying cause | |||
===Treat Underlying Cause=== | |||
*Discontinue or reduce offending medication (cyclosporine, tacrolimus, chemotherapy) | |||
*Delivery for eclampsia/preeclampsia with severe features | |||
*Treat [[sepsis]], [[renal failure]], autoimmune flare as indicated | |||
*Dialysis for uremic patients | |||
===Monitoring=== | |||
*ICU admission for most patients | |||
*Continuous BP monitoring (arterial line preferred) | |||
*Serial neurologic exams | |||
*Repeat MRI at 1-2 weeks to confirm resolution of edema | |||
==Prognosis== | |||
*Majority of cases are fully reversible within days to weeks with appropriate treatment | |||
*Risk factors for poor outcome: | |||
**Restricted diffusion on DWI (cytotoxic edema → infarction) | |||
**Hemorrhage | |||
**Delayed diagnosis and treatment | |||
**Untreated PRES can progress to permanent brain injury | |||
==Disposition== | ==Disposition== | ||
*Admit | *Admit to ICU for BP monitoring, seizure management, and neurologic observation | ||
*Neurology consultation | |||
*Nephrology if drug-related (immunosuppressant dose adjustment) | |||
*OB consultation if eclampsia/preeclampsia | |||
==See Also== | ==See Also== | ||
[[Hypertensive | *[[Eclampsia]] | ||
[[ | *[[Preeclampsia]] | ||
*[[Hypertensive emergency]] | |||
*[[Status epilepticus]] | |||
*[[Ischemic stroke]] | |||
*[[Cerebral venous sinus thrombosis]] | |||
==References== | ==References== | ||
*Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. ''Lancet Neurol''. 2015;14(9):914-925. PMID 26184985 | |||
*Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. ''AJNR Am J Neuroradiol''. 2008;29(6):1043-1049. PMID 18403560 | |||
*Hinchey J, et al. A reversible posterior leukoencephalopathy syndrome. ''N Engl J Med''. 1996;334(8):494-500. PMID 8559202 | |||
*Liman TG, et al. Clinical and radiological differences in posterior reversible encephalopathy syndrome between patients with preeclampsia-eclampsia and other predisposing diseases. ''Eur J Neurol''. 2012;19(7):935-943. PMID 22248339 | |||
[[Category:Neurology]] | |||
[[Category:Critical Care]] | |||
Latest revision as of 09:57, 22 March 2026
Background
- Clinical-radiographic syndrome characterized by headache, seizures, visual disturbances, and altered mental status with vasogenic edema predominantly in posterior brain regions[1]
- Previously known as reversible posterior leukoencephalopathy syndrome (RPLS)
- Usually reversible with prompt treatment of underlying cause, but can be irreversible if untreated (cytotoxic edema, hemorrhage)
- Pathophysiology (two proposed mechanisms):
- Hypertensive theory: severe hypertension exceeds cerebral autoregulation → hyperperfusion → vasogenic edema (posterior brain more vulnerable due to less sympathetic innervation)
- Endothelial dysfunction theory: direct endothelial injury from toxins, medications, or autoimmune activation → blood-brain barrier disruption → vasogenic edema
Common Causes
- Hypertensive emergency (most common; including eclampsia/preeclampsia)
- Immunosuppressive/cytotoxic medications: cyclosporine, tacrolimus, cisplatin, bevacizumab, methotrexate
- Autoimmune conditions: SLE, thrombotic thrombocytopenic purpura, hemolytic uremic syndrome
- Renal failure (especially with fluid overload)
- Eclampsia/preeclampsia (most common cause in young women)
- Sepsis, shock, organ transplantation
Clinical Features
- Headache (most common presenting symptom)
- Seizures (60-75% of cases; may be the presenting feature)
- Visual disturbances: blurred vision, cortical blindness, visual neglect, homonymous hemianopia
- Altered mental status: confusion, obtundation, decreased alertness
- Focal neurologic deficits (less common but can occur)
- Hypertension (present in 70-80% but PRES can occur with normal BP in 20-30% of cases)
- Nausea, vomiting
Differential Diagnosis
- Ischemic stroke (especially posterior circulation)
- Cerebral venous sinus thrombosis
- Encephalitis
- CNS vasculitis
- Toxic leukoencephalopathy
- Demyelinating disease (ADEM)
- Subarachnoid hemorrhage
- Status epilepticus
- CNS metastatic disease
Evaluation
MRI (Diagnostic Study of Choice)
- MRI with FLAIR and DWI is the gold standard
- Classic pattern: bilateral, symmetric vasogenic edema in parieto-occipital white matter
- FLAIR/T2: hyperintense signal in affected regions
- DWI/ADC: elevated ADC (vasogenic edema) vs restricted diffusion (cytotoxic edema → worse prognosis)
- Atypical patterns (30-40%): frontal lobe, temporal lobe, cerebellum, brainstem, unilateral, hemorrhagic
- Hemorrhage occurs in 5-15% of cases (petechial or frank hemorrhage)
CT Head
- May show hypodensity in posterior regions but sensitivity is low
- Useful to rule out hemorrhage or ischemic stroke initially
- If MRI unavailable, CT findings may be suggestive but are often subtle
Labs
- BMP (renal function, electrolytes)
- CBC with smear (evaluate for TMA — schistocytes if TTP/HUS)
- LFTs, LDH, haptoglobin (hemolysis workup)
- Urinalysis (proteinuria if eclampsia)
- Magnesium level
- Drug levels (cyclosporine, tacrolimus)
- Pregnancy test in reproductive-age women
Management
Blood Pressure Control (If Hypertensive)
- Gradual reduction — target 25% reduction in MAP in first few hours
- Avoid precipitous drops (risk of posterior circulation ischemia)
- Preferred agents:
- Nicardipine infusion 5-15 mg/hr (easily titratable)
- Labetalol 10-20 mg IV q10-20min
- If eclampsia: magnesium sulfate is first-line for seizure prevention (see eclampsia)
Seizure Management
- Benzodiazepines for acute seizures (lorazepam 2-4 mg IV)
- AEDs for ongoing seizure prophylaxis (levetiracetam preferred)
- If eclampsia: magnesium sulfate (primary treatment)
- Most seizures resolve with BP control and treatment of underlying cause
Treat Underlying Cause
- Discontinue or reduce offending medication (cyclosporine, tacrolimus, chemotherapy)
- Delivery for eclampsia/preeclampsia with severe features
- Treat sepsis, renal failure, autoimmune flare as indicated
- Dialysis for uremic patients
Monitoring
- ICU admission for most patients
- Continuous BP monitoring (arterial line preferred)
- Serial neurologic exams
- Repeat MRI at 1-2 weeks to confirm resolution of edema
Prognosis
- Majority of cases are fully reversible within days to weeks with appropriate treatment
- Risk factors for poor outcome:
- Restricted diffusion on DWI (cytotoxic edema → infarction)
- Hemorrhage
- Delayed diagnosis and treatment
- Untreated PRES can progress to permanent brain injury
Disposition
- Admit to ICU for BP monitoring, seizure management, and neurologic observation
- Neurology consultation
- Nephrology if drug-related (immunosuppressant dose adjustment)
- OB consultation if eclampsia/preeclampsia
See Also
- Eclampsia
- Preeclampsia
- Hypertensive emergency
- Status epilepticus
- Ischemic stroke
- Cerebral venous sinus thrombosis
References
- Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914-925. PMID 26184985
- Bartynski WS. Posterior reversible encephalopathy syndrome, part 2: controversies surrounding pathophysiology of vasogenic edema. AJNR Am J Neuroradiol. 2008;29(6):1043-1049. PMID 18403560
- Hinchey J, et al. A reversible posterior leukoencephalopathy syndrome. N Engl J Med. 1996;334(8):494-500. PMID 8559202
- Liman TG, et al. Clinical and radiological differences in posterior reversible encephalopathy syndrome between patients with preeclampsia-eclampsia and other predisposing diseases. Eur J Neurol. 2012;19(7):935-943. PMID 22248339
- ↑ Fugate JE, Rabinstein AA. Posterior reversible encephalopathy syndrome: clinical and radiological manifestations, pathophysiology, and outstanding questions. Lancet Neurol. 2015;14(9):914-925. PMID 26184985
